Warren, R.B., Reich, K., Simpson, E.L., Langley, R., Costanzo, A., Saeki, H., Almgren, P., Vacko, E., Gooderham, M., Deleuran, M., Francisco Silvestre, J., Weidinger, S. and Blauvelt, A. 2022. 3 years of tralokinumab treatment provides long-term disease control as demonstrated by clinically meaningful outcomes in moderate-to-severe atopic dermatitis. SKIN The Journal of Cutaneous Medicine. 6, 6 (Nov. 2022), s78. DOI:https://doi.org/10.25251/skin.6.supp.78.